WO2010151074A3 - Conjugués contenant des photosensibilisateurs constitués de points quantiques et de dérivés de chlore et composition pour traiter et diagnostiquer un cancer contenant ces conjugués pour mettre en oeuvre une thérapie photodynamique - Google Patents

Conjugués contenant des photosensibilisateurs constitués de points quantiques et de dérivés de chlore et composition pour traiter et diagnostiquer un cancer contenant ces conjugués pour mettre en oeuvre une thérapie photodynamique Download PDF

Info

Publication number
WO2010151074A3
WO2010151074A3 PCT/KR2010/004134 KR2010004134W WO2010151074A3 WO 2010151074 A3 WO2010151074 A3 WO 2010151074A3 KR 2010004134 W KR2010004134 W KR 2010004134W WO 2010151074 A3 WO2010151074 A3 WO 2010151074A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
composition
diagnosing cancer
quantum dot
photodynamic therapy
Prior art date
Application number
PCT/KR2010/004134
Other languages
English (en)
Korean (ko)
Other versions
WO2010151074A2 (fr
Inventor
안웅식
배수미
바토그토크흐간트므르
문란영
Original Assignee
주식회사 진코스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 진코스 filed Critical 주식회사 진코스
Publication of WO2010151074A2 publication Critical patent/WO2010151074A2/fr
Publication of WO2010151074A3 publication Critical patent/WO2010151074A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

La présente invention concerne des conjugués contenant des photosensibilisateurs constitués de points quantiques et de dérivés de chlore et une composition pour traiter et diagnostiquer un cancer contenant ces conjugués pour mettre en oeuvre une thérapie photodynamique. Les conjugués de la présente invention peuvent être utilisés en tant que médicament unique pour traiter et diagnostiquer un cancer.
PCT/KR2010/004134 2009-06-26 2010-06-25 Conjugués contenant des photosensibilisateurs constitués de points quantiques et de dérivés de chlore et composition pour traiter et diagnostiquer un cancer contenant ces conjugués pour mettre en oeuvre une thérapie photodynamique WO2010151074A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090057910 2009-06-26
KR10-2009-0057910 2009-06-26

Publications (2)

Publication Number Publication Date
WO2010151074A2 WO2010151074A2 (fr) 2010-12-29
WO2010151074A3 true WO2010151074A3 (fr) 2011-05-19

Family

ID=43387066

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/004134 WO2010151074A2 (fr) 2009-06-26 2010-06-25 Conjugués contenant des photosensibilisateurs constitués de points quantiques et de dérivés de chlore et composition pour traiter et diagnostiquer un cancer contenant ces conjugués pour mettre en oeuvre une thérapie photodynamique

Country Status (2)

Country Link
KR (1) KR101288460B1 (fr)
WO (1) WO2010151074A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2717920A4 (fr) * 2011-06-11 2015-04-29 Univ Central Florida Res Found Nanosondes activables pour une administration intracellulaire de médicament
KR101668561B1 (ko) 2015-07-13 2016-10-21 원광대학교산학협력단 녹색형광단백질을 발현하는 유전자 및 로즈 벵갈을 이용한 암 질환의 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법
US20170049891A1 (en) * 2015-08-17 2017-02-23 Nanoco Technologies Ltd. 5-aminolevulinic acid conjugated quantum dot nanoparticle
RU2638446C1 (ru) * 2016-12-14 2017-12-13 федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский ядерный университет МИФИ" (НИЯУ МИФИ) Способ направленного разрушения раковых клеток
KR101911725B1 (ko) 2017-01-16 2018-12-28 주식회사 코어파마 적색형광단백질을 발현하는 유전자 및 틴 에틸 에티오푸르푸린을 이용한 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법
CN107722075A (zh) * 2017-10-09 2018-02-23 大连理工大学 一类二氢卟吩葡萄糖苷类化合物及其制备方法与应用
KR102277244B1 (ko) * 2019-09-03 2021-07-13 인제대학교 산학협력단 생체 영상화 및 광열치료용 탄소양자점-폴리피롤 나노 복합체 및 이의 제조방법
KR102256817B1 (ko) 2019-09-09 2021-05-26 한국교통대학교산학협력단 자가 치유 전기화학적 무선진단이 가능한 탄소양자점 기반 수화젤의 제조방법 및 이를 활용한 자기 치유 전기화학적 무선진단방법
KR102294374B1 (ko) 2019-09-09 2021-08-26 한국교통대학교산학협력단 전기화학적 무선 진단이 가능한 탄소 양자점의 제조방법, 및 이를 활용한 전기화학적 무선진단방법
CN114933904B (zh) * 2022-06-14 2024-02-06 中国医科大学 一种用于光学诊疗的超薄壳层手性硒化镉/硫化镉材料及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080104495A (ko) * 2007-05-28 2008-12-03 전남대학교산학협력단 양자점을 이용한 생물학적 검출키트 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080104495A (ko) * 2007-05-28 2008-12-03 전남대학교산학협력단 양자점을 이용한 생물학적 검출키트 및 방법

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BECHET, DENISE ET AL.: "Nanoparticles as vehicles for delivery of photodynamic therapy agents", TRENDS IN BIOTECHNOLOGY, vol. 26, no. 11, 2008, pages 612 - 621 *
CHO, SUNG JU ET AL.: "Long-Term Exposure to CdTe Quantum Dots Causes Functional Impairments in Live Cells", LANGMUIR, vol. 23, 2007, pages 1974 - 1980 *
SHAN, YAMING ET AL.: "NHS-mediated QDs-peptide/protein conjugation and its application for cell labeling", TALANTA, vol. 75, 2008, pages 1008 - 1014, XP022624863, DOI: doi:10.1016/j.talanta.2007.12.040 *
TSAY, M. JAMES ET AL.: "Singlet Oxygen Production by Peptide-Coated Quantum Dot- Photosensitizer Conjugates.", J. AM. CHEM. SOC., vol. 129, 2007, pages 6865 - 6871 *

Also Published As

Publication number Publication date
KR101288460B1 (ko) 2013-07-26
WO2010151074A2 (fr) 2010-12-29
KR20110000524A (ko) 2011-01-03

Similar Documents

Publication Publication Date Title
WO2010151074A3 (fr) Conjugués contenant des photosensibilisateurs constitués de points quantiques et de dérivés de chlore et composition pour traiter et diagnostiquer un cancer contenant ces conjugués pour mettre en oeuvre une thérapie photodynamique
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
CY1118061T1 (el) Δικυκλικα παραγωγα heterocyclyl σαν καταστολεις κινασης (kinase) fgfr για θεραπευτικη χρηση
IL245889B (en) Sulfonamide derivatives as bcl-2-selective apoptosis inducers for the treatment of cancer and immune diseases
NZ595372A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
MX2011013306A (es) Compuestos tetraciclicos.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082273A3 (fr) Composés de pyrroloaminopyrimidine substitués
IN2012DN02081A (fr)
WO2011082267A8 (fr) Composés triazolo-pyrazine substitués
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
EP2331520A4 (fr) Dérivés de rosamine comme agents pour le traitement d'un cancer
PH12015500252A1 (en) Niclosamide for the treatment of solid tumors
WO2009095261A3 (fr) Compositions vaccinales
WO2012040105A3 (fr) Cellules transfectées par renilla/gaussia
BR112012019302A2 (pt) imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met
WO2011082268A3 (fr) Composés naphthalényl-pyrimidine substitués
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
WO2012061413A3 (fr) Compositions d'isoflavonoïdes et méthodes de traitement du cancer
WO2013096335A8 (fr) Administration d'un antagoniste de l'intégrine alpha-5-bêta 1 afin de lutter contre l'angiogenèse et de traiter le cancer
GB0706335D0 (en) Porphyrin compounds
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
AU2013357030A8 (en) Chlorin derivative useful in photodynamic therapy and diagnosis
WO2009088992A3 (fr) Composés à base de ribonucléase et de thiazolidinedione et leur utilisation dans des procédés de traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10792356

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 06.03.2012)

122 Ep: pct application non-entry in european phase

Ref document number: 10792356

Country of ref document: EP

Kind code of ref document: A2